FDA Grants Priority Review Voucher for Rare Pediatric Drug
Published Date: 5/11/2026
Notice
Summary
The FDA just gave Denali Therapeutics a special priority review voucher for their rare pediatric disease drug AVLAYAH, approved in March 2026. This voucher speeds up the review of future medicines, helping kids with rare diseases get treatments faster. It’s a big win for patients, the company, and anyone watching rare disease drug development!
Free Policy Watch
New rules are filed every week. Most people never see them.
Pick a topic. PRIA watches every federal rule and tells you when one hits your household.
Pick a topic to get started
Analyzed Economic Effects
2 provisions identified: 2 benefits, 0 costs, 0 mixed.
New FDA Approval for Hunter Syndrome Pediatrics
AVLAYAH (tividenofusp alfa-eknm) was approved March 24, 2026 for the treatment of neurologic manifestations of Hunter syndrome (Mucopolysaccharidosis type II). The approval applies when treatment is started in presymptomatic or symptomatic pediatric patients weighing at least 5 kg prior to advanced neurologic impairment.
Priority Review Voucher Awarded to Sponsor
The FDA issued a priority review voucher to Denali Therapeutics Inc. for AVLAYAH (tividenofusp alfa-eknm); AVLAYAH was approved March 24, 2026. The voucher was awarded under section 529 of the Federal Food, Drug, and Cosmetic Act.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Take It Personal
Get Your Personalized Policy View
Take the PRIA Score to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in